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This study explores the differential protein expression in the colorectal cancer (CRC) patients to validate a new 
biomarker for tumor progression. CRC tissues and their adjacent non-cancerous tissues were analyzed by two-dimensional 
LC/MS/MS. Nucleophosmin 1 (NPM1) was selected and confirmed its differential expression by Western blot. 
Immunohistological staining of NPM1 in tissues was performed to validate its correlation with clinicopathologic parameters 
of CRC patients. There were 39 candidates with significant difference between cancerous tissues and their adjacent  
non-cancerous tissues, which included 19 increased proteins and 20 decreased proteins in CRC samples. Especially, NPM1 was 
correlated with poor differentiation, and lymph node metastasis according to the analysis of patients’ clinicopathologic parameters. 
Increased expression of NPM1 can be as a critical biomarker for clinical diagnosis of tumor progression of CRC patients. 
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Colorectal cancer (CRC) is the fourth-leading cause of 
cancer-related deaths globally
1
. Its prognosis largely 
depends on the stage of CRC, with 5-year overall 
survival (OS) ranging from close to 90% for early-stage 
cancer to little over 10% for advanced-stage cancer even 
in the well-developed countries
2
. That is, patients  
with early-stage CRC can obtain benefits from surgical 
resection combined with systemic chemotherapy
3
. 
However, the 5 year OS of patients with advanced  
CRC is only 60%, which might be due to only partial 
patients can respond to the chemotherapeutic agent  
5-fluorouracil (5-FU), irinotecan or oxaliplatin, and  
are easily prone to recurrence
4
. 
So far, some molecular mechanisms can partially 
elucidate the phenomena of recurrence and poor 
prognosis of CRC patients. For example, the genetic 
variants in some biological pathways involved in drug 
transportation or metabolism, repair of DNA damage, 
and cell cycle modulation, which might affect the 
efficacy of oxaliplatin treatment in patients with 
advanced CRC
5
. In addition, serum level of miR-760 
with higher diagnostic power and miR-92a with higher 
prognostic power for the discrimination between CRC 
stages in Egyptian patients have also been proven
6
. 
However, these prognostic biomarkers are still not 
enough for identifying advanced-stage CRC patients 
with high risk of recurrence after surgical resection. 
Although the advancements in the molecular diagnosis 
and targeted therapy of CRC, identification of new 
diagnostic biomarkers continues to be a challenge
7
. 
Nucleophosmin (NPM), also known as nucleolar 
phosphoprotein B23 or numatrin, is a protein encoded 
by the NPM1 gene in humans
8
. It is located in the 
nucleolus, and can be translocated to the nucleoplasm 
in response to serum starvation or treatment with 
anticancer drugs. NPM1 plays an essential role in cell 
growth and proliferation by regulating cell cycle 
progression and centrosome duplication
9,10
. NPM has 
multiple functions, including genomic stability and 
DNA repair, centrosome duplication during cell cycle, 
and inhibition of caspase-activated DNase. Other 
studies also demonstrated that NPM1 can regulate the 
activity of several tumor suppressors, including P53 
and Rb via direct binding
11
. It is also involved in 
transcriptional activation through interaction with 
transcription factors, such as c-Myc and NF-κB12. 
—————— 
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NPM1 has also been proven to be associated with 
several cancers, including prostate, liver, gastric, colon, 
pancreas, glioma and glioblastoma, astrocytoma and 
others
13,14
. 
In the present study, we analyzed the expression 
values of candidates from the CRC and the adjacent 
non-cancerous tissues by using two-dimensional 
LC/MS/MS. NPM1 protein was selected to measure its 
increased expression in CRC patients by using Western 
blot and immunohistological staining, and then further 
analyzed with the clinicopathologic parameters of 
patients by using statistics. 
Materials and Methods 
 
Patients 
The study was performed in accordance with the 
Helsinki Declaration and was also approved by Ethics 
Committee at China-Japan Union Hospital of Jilin 
University. Patients with CRC had been given verbal 
explanations and had signed informed consent before 
surgery began. Forty patients in the study were clinically 
or pathologically diagnosed as stage III colorectal 
adenocarcinoma，who had not received any therapy 
before the surgery began (Table 1). Specimens from the 
cancerous tissues and their adjacent non-cancerous 
Table 1 — Clinicopathologic characteristics and stages of CRC patients 
No. Gender Age Differentiation TNM stage 
1 Male 68 Moderately T1N0M0 
2 Female 48 Poorly Differentiation T1N1M0 
3 Male 40 Poorly Differentiation T1N2aM0 
4 Male 68 Moderately T1N2bM1a 
5 Male 46 Well T2N0M0 
6 Female 71 Well T2N0M0 
7 Female 50 Poorly Differentiation T2N1M0 
8 Male 58 Poorly Differentiation T2N1M0 
9 Male 52 Poorly Differentiation T2N1M0 
10 Male 44 Poorly Differentiation T2N1M0 
11 Female 54 Well T3N0M0 
12 Female 49 Moderately T3N0M0 
13 Male 46 Poorly Differentiation T3N0M0 
14 Male 54 Poorly Differentiation T3N1M0 
15 Male 49 Poorly Differentiation T3N1M0 
16 Male 43 Poorly Differentiation T3N1M0 
17 Male 36 Moderately T3N1M1a 
18 Male 37 Poorly Differentiation T3N2bM0 
19 Female 51 Moderately T4aN0M0 
20 Male 53 Moderately T4aN0M0 
21 Female 52 Poorly Differentiation T4aN0M0 
22 Male 61 Moderately T4aN0M0 
23 Male 74 Moderately T4aN0M0 
24 Female 60 Poorly Differentiation T4aN1aM0 
25 Male 52 Poorly Differentiation T4aN1M0 
26 Male 59 Poorly Differentiation T4aN1M0 
27 Male 65 Poorly Differentiation T4aN1M0 
28 Female 46 Poorly Differentiation T4aN1M1a 
29 Female 54 Poorly Differentiation T4aN1M1a 
30 Male 56 Moderately T4bN0M0 
31 Female 54 Poorly Differentiation T4bN0M0 
32 Male 50 Moderately T4bN0M0 
33 Male 54 Moderately T4bN1M0 
34 Female 59 Poorly Differentiation T4bN1M0 
35 Male 48 Poorly Differentiation T4bN2bM0 
36 Male 48 Poorly Differentiation T4bN2bM1a 
37 Male 54 Poorly Differentiation T4N1M0 
38 Male 51 Poorly Differentiation T4N1M0 
39 Male 47 Poorly Differentiation T4N1M0 
40 Male 50 Poorly Differentiation T4N1M0 
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tissues (10 cm away from the cancerous tissues) were 
collected to freeze in a −80C refrigerator immediately 
after resection, then stored in liquid nitrogen. 
 
Reagents 
N,N,N',N'-Tetramethylethylenediamine, monoclonal 
antibody against NPM1, Sodium Dodecyl Sulfate 
(SDS), absolute alcohol, RCDC Protein Assay Kit 
were purchased from Bio-Rad (Richmond, CA). DAB 
staining kit, bromophenol blue, citric acid antigen 
retrieval agent, Coomas bright blue, Xylene,  
mineral oil, modified hematoxylin, and PMSF were 
obtained from Sigma-Aldrich (St. Louis, MO). 
Iodoacetamide (IAM), goat anti-rabbit IgG, 3% H2O2, 
DTT, TPCK-trypsin were from Promega (Madison 
WI). Dehydration machine (Tissue-Tek VIP Sakura) 
and Agilent 1200 nanoflow LC system were from 
Agilent Technologies (Wilmington, DE). Embedding 
machine (Tissue-TekVIP TEC) and LTQ Orbitrap XL 
MS/MS spectrometer were from Thermo Fisher (San 
Jose, CA). Tissue slicer (LEICA SM 2000) was from 
Leica Microsystem (Nussloch, Germany). 
 
Two-dimensional LC/MS/MS 
The frozen samples were digested followed by strong 
cation exchange-RPLC/MS/MS as briefly described 
following. The frozen samples were treated with  
DTT and alkylated with IAM before digestion with 
trypsin. The separations of peptides were achieved  
using an Agilent 1200 nanoflow LC system (Agilent 
Technologies) by using strong cation exchange column 
(150 mm × 0.32 mm) coupled with reverse-phase 
column (150 mm × 0.17 mm). Fifty g of peptides in 
Buffer A (0.1% FA) were operated by using a mobile 
phase with ammonium acetate, which concentrations 
were linearly increased from 0 mM to 1 M (0 mM,  
25 mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 
and 1 M). The reverse-phase column was operated in 
30% Buffer B (0.1% formic acid and 99% acetonitrile) 
with 2 µL/min flow rate for 3 h. Peptide analysis was 
carried out using a Thermo LTQ Orbitrap XL MS/MS 
spectrometer (San Jose, CA, USA) with data-dependent 
MS/MS scan over the m/z range 400-2000 by 35% 
normalized collision energy. Thermo Bioworks 3.3.1 
SP1 with SEQUEST was used to search against the 
database ipi.human.v3.05, and results were filtered using 
standard values for Xcorr and ΔCN.  
The SEQUEST criteria was performed as follows: 
mass tolerance = 3 Da; 2 leakage points; a 
modification of +57 Da on cysteine residue; FPR=1%, 
Δ Cn ≥0.19; Xcorr = 2.2 for +1 charged peptides; 
Xcorr = 2.5 for +2 charged peptides; Xcorr = 2.9 for 
+3 charged peptides. 
 
Western blot analysis 
Protein (20 µg) from each tissue sample was 
denatured and separated by 10% SDS-polyacrylamide 
gel electrophoresis, and then transferred onto 
polyvinylidene difluoride membranes (EMD Millipore, 
Billerica, MA). The membranes were blocked in 5% 
skim milk at 4C for overnight, and then incubated 
with the anti-NPM1 antibody (dilution 1:200 in 5% 
BSA-PBS) for 2 h at RT. After washing 3 times in 1X 
PBST, the membranes were subsequently incubated 
with HRP-conjugated anti-IgG secondary antibody 
(dilution, 1:10000) and then washed 3 times in 1X 
PBST. The proteins were visualized by using an 
enhanced chemiluminescence reagent (Pierce; Thermo 
Fisher Scientific, Inc.) according to the manufacturer's 
protocol. The intensity of the images was quantified 
by using ImageJ software (National Institute of 
Health, USA). An anti-β-actin mouse monoclonal 
antibody (dilution 1:1000 in 5% BSA-PBS) was used 
to normalize the protein loading. 
 
Immunohistological staining 
Paraffin-embedded tissue samples were heated in 
60℃ incubator for 20 min, followed by being 
dewaxed in xylene for 5 min twice, rehydrated with 
graded alcohol solutions, and put in distilled water for 
5 min twice. Antigen retrieval was conducted by 
autoclaving the slides for 10 min in 0.01 mol/L 
sodium citrate buffer, pH 6.0. After cooling down,  
the slides were washed with 1X PBS for 5 min. 
Endogenous peroxidase was blocked by incubation in 
fetal calf serum for 10 min, and followed by washing 
in PBS for 3 min 3 times. The tissue sections were 
then incubated at RT for 60 min with antibody against 
NPM1 (dilution, 1:200), and followed by washing in 
PBS for 5 min 3 times. The antigen-antibody complex 
was then detected with a biotinylated goat anti-rabbit 
antibody at RT for 10 min, and washed in PBS for  
3 min 3 times. The slides were then incubated with 
streptoavidin-horseradish peroxidase for 10 min, 
washed in PBS for 3 min 3 times, and then visualized 
by staining with 50 L diaminobenzidine (DAB) for  
5 min for color detection. The tissue sections were 
then counterstained with hematoxylin for 2-3 min, 
and dehydrated with graded alcohol solutions for 
mounting. The samples were observed and photographed 
with an optical microscope. Tumor grade was evaluated 
according to the grading system established by the 
World Health Organization in 2004. 
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Statistical analysis 
Raw files from two-dimensional LC/MS/MS were 
analyzed by using SEQUEST algorithm. Statistical 
analysis was conducted with SPSS version 11.0, and 
reported as mean ± standard deviation (SD). The  
P-value less than 0.01 (0.05/5=0.01) was considered 
to be statistical significance according to Bonferroni 
correction. 
 
Results 
 
Differential expression of 39 proteins detected by two-dimensional 
LC/MS/MS 
In the present study, the number of spectra of the 
two-dimensional LC/MS/MS was used to evaluate the 
abundance of proteins. The criteria of the significant 
differences between two groups was defined as 
follows. First, the difference in the number of protein 
spectra of the two samples should larger than 72; 
Second, the ratio of the numbers of protein spectra in 
two groups should larger than 1. There were 39 
proteins with significant difference between cancerous 
tissues and their adjacent non-cancerous tissues 
according to the above criteria (Table 2). Among them, 
19 proteins were increased, however, 20 proteins were 
decreased in CRC samples (Table 2). These targets 
might be the highly promising sensitive and specific 
tumor markers of CRC, and need to be validated 
clinically in the future. The identification of NPM1 
with two-dimensional LC/MS/MS was shown in 
(Table 3 and Fig. 1). 
 
Increased expression of NPM1 in the CRC tissues 
The differential expression of NPM1 in the two 
groups was confirmed by Western blot analysis. The 
Table 2 — Expressions of differential proteins in CRC and adjacent non-cancerous tissues 
 Proteins 
Up-regulation in CRC (19) KRT18, ATP5B, NPM1, TPM4, FGA, HSPA5, MUC2, IGHA1, SERPINH1, ENO1, TPM3, CKAP4, 
IGHA2, POSTN, COL6A3, FGG, PKM2, HIST1H2AE, MYH10 
Down-regulation in CRC(20) SYNM, MYH11, PKM2, MYL9, KRT10, TPM1, FLNC, DES, H2AFX, CSRP1, CAP1, CNN1, MYL6, 
ACTA2, TUBB2A, HSPB1, TLN1, ACTA1, FLNA, CKB 
 
Table 3 — Identification of NPM1 by LC/MS/MS 
IPI number Protein Name Sequence Charge Parent Ion  
Mass 
M+H+ 
Deviation 
XCorr DeltaCn 
IPI:IPI00549248 NPM1 Isoform 1 of 
Nucleophosmin 
R.TVSLGAGAKDELHIVEAEAMNYEG
SPIKVTLATLK.M 
3 3658.1175 0.0205 7.023 0.637 
IPI:IPI00549248 NPM1 Isoform 1 of 
Nucleophosmin 
R.MTDQEAIQDLWQWR.K 2 1821.0065 0.1451 3.387 0.326 
IPI:IPI00549248 NPM1 Isoform 1 of 
Nucleophosmin 
K.MSVQPTVSLGGFEITPPVVLR.L 2 2228.6401 0.7745 5.03 0.627 
IPI:IPI00549248 NPM1 Isoform 1 of 
Nucleophosmin 
K.ADKDYHFKVDNDENEHQLSLR.T 3 2574.7039 0.022 5.364 0.273 
 
 
 
Fig. 1 — Peptide sequence of NPM1 from the results of LC/MS/MS. The peptide sequence “ADKDYHFKVDNDENEHQLSLR” was 
shown to identify NPM1 by using two-dimensional LC/MS/MS 
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expression of NPM1 was higher in the cancerous 
tissues than in the non-cancerous tissues (Fig. 2A & B). 
The results were consistent with those from  
two-dimensional LC/MS/MS analysis. 
In addition, high expression of NPM1 in cancerous 
tissues was also observed by using immune histological 
staining. It indicated that NPM1 was located 
predominantly at the cytoplasm (Fig. 2C & D). 
Significant association of NPM1 with clinicopathologic 
characteristics of CRC patients 
We further analyzed the correlation of NPM1 
expression with clinicopathologic characteristics in CRC 
patients. The expression of NPM1 was higher in  
patients with poorly differentiation than in patients  
with moderately/well differentiation (P< 0.05) (Tables 4  
and 5). 18 out of 22 CRC patients with lymph node 
 
 
Fig. 2 — Different expression of NPM1 protein in carcinoma tissues and adjacent non-cancerous tissues. (A & B) The expression of 
NPM1 protein in carcinoma tissues is significantly higher than that in adjacent non-cancerous tissues; (C & D) Comparison with adjacent 
non-cancerous tissues, NPM1 protein in tumor tissues revealed strong expression; and (E) Normal tissue was shown (× 40) 
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metastasis (81.9%) were NPM1 positive, 9 out of 18 
CRC patients without lymph node metastasis (50%) 
were NPM1 negative (P< 0.05). The results indicated 
that NPM1 expression was significantly associated with 
differentiation and lymph node metastasis, but was not 
associated with tumor size, gender and age of patients 
(P> 0.05) (Tables 4 and 5). 
 
Discussion 
CRC is one of the most common tumors in China, 
with increasing incidence annually. Its prognosis and 
the OS are closely related with sensitive and specific 
diagnosis in the early stage. Some studies reported 
that patients received the surgery at early-stage of 
CRC exhibited a higher 5 year OS close to 90%
2
. 
Therefore, exploring the molecular biomarkers for 
early diagnosis or recurrence after therapy is crucial 
to increase CRC patients’ survival rates. 
By using two-dimensional LC/MS/MS, we found 
several proteins differentially expressed between  
CRC and its adjacent non-cancerous tissues (Table 2). 
Among them, NPM1 was interesting to us to further 
validate its clinical roles in CRC. In CRC cells,  
Wong et al. proved that NPM1 can affect p53-related 
aging and growth arrest, indicating that NPM1 
promotes tumorigenesis
15
. Liu et al. also 
demonstrated that high expression of NPM1 is 
associated with distant metastasis and poor survival  
in CRC patients
16
. In the present study, we further 
demonstrated that increased NPM1 expression in 
patients was associated with poorly differentiation 
and lymph node metastasis (Tables 4 & 5). It 
indicates that NPM1 can be utilized in the clinical 
diagnosis for the CRC patients’ progression according 
to the tumor grade. However, its roles in CRC need to 
be further elucidated. 
It was first demonstrated the NPM1 is related to 
about one-third of anaplastic large-cell non-Hodgkin’s 
lymphomas, and linked to the catalytic domain of 
anaplastic lymphoma receptor tyrosine kinase 
(ALK)
17
. In addition, NPM1 overexpression in solid 
tumors is associated with poor prognosis, including 
astrocytomas
18
, oral squamous cell carcinoma,  
non-small cells lung cancer (NSCLC), hepatocellular 
carcinomas (HCC), colon cancer, ovarian cancer, and 
endometrial carcinoma
19
. Londero et al. revealed a 
link between an overexpression of nuclear NPM1 
protein and poor outcomes for women diagnosed with 
high-grade ovarian serous cancer
20
. Kalra et al. 
elucidated a functional relevance of NPM1, RAD50 
and XRCC5 DSB-repair proteins towards ensuring 
survival and evasion of apoptosis during ovarian 
Table 4 — NPM1 expression in CRC and adjacent non-cancerous tissues 
Type Sample (n) NPM1 expression P-value 
  + −  
CRC tissue 100 72 (72.0%) 28 (28.0%) 0.008 
Adjacent non-cancerous tissue 100 46 (46.0%) 54 (54.0%)  
 
Table 5 — Correlation of NPM1 expression with clinical-pathologic characteristics of CRC patients 
Parameters Sample (n) NPM1 P-value 
  Positive (%) Negative (%)  
Gender     0.605 
 Male 53 37 (69.8%) 16 (30.2%)  
 Female 47 35 (74.5%) 12 (25.5%)  
Age     0.342 
 <55 39 26 (66.7%) 13 (33.3%)  
 ≥55 61 46 (75.4%) 15 (24.6%) 
Differentiation     0.001 
 Moderately/Well 35 18 (51.4%) 17 (48.6%)  
 Poorly Differentiation 65 54 (83.1%) 11 (16.9%) 
Lymph node 
metastasis 
    0.001 
 Nx 71 58 (81.7%) 13 (18.3%)  
 N0 29 14 (48.3%) 15 (51.7%) 
Tumor size     0.137 
 T1-T2 10 5 (50%) 5 (50%)  
 T3-T4 90 67 (74.4%) 23 (25.6%) 
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transformation to emphasize their contribution and 
association with disease progression in high- 
grade Serous Ovarian Carcinoma
21
. Furthermore, 
chemotherapeutic sensitivity is poor in lung 
adenocarcinoma patients with overexpression of c-Src 
and NPM1 protein, which indicates higher expression 
of c-Src and NPM1 might be associated with poorly 
differentiated adenocarcinoma
22
.  
Taken together, we suggest that NPM1 plays 
critical roles in the CRC development, migration/ 
invasion, and progression. It is also interesting to us to 
explore the cross-talk of NPM1 with other biomarkers 
or oxidative stress of CRC, which indicates to be 
critical to tumor differentiation and progression
23
.  
 
Conclusion 
Based on our findings and the contribution of 
NPM1 in other cancers and in the genome stability, it 
might be a promising target to utilize in the diagnosis, 
prognosis, and even in the therapeutic strategy to 
CRC patients. Increased expression of NPM1 can be 
as a critical biomarker for clinical diagnosis of tumor 
progression of CRC patients. 
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